Lipomas are the most common benign mesenchymal tumors, primarily composed of mature adipocytes. They are often asymptomatic but may require intervention due to growth or compression effects, impacting both function and aesthetics. Their exact incidence is poorly characterized owing to underreported asymptomatic cases, and current pathological classifications remain inconsistent. While genetic factors (e.g., chromosome 12 rearrangements) and trauma history are implicated, systematic investigations into metabolic, hormonal, and demographic risk factors (e.g., obesity, age, sex) are lacking. This study seeks to bridge this gap by exploring retrospective clinical data from UK Biobank (UKB) to elucidate lipoma pathogenesis and heterogeneity.
The study will address three key questions: (1) What are the primary risk factors (e.g., age, BMI, metabolic profiles, trauma) for lipoma development? (2) Do risk profiles vary across pathological subtypes (e.g., conventional vs. vascular lipomas)? (3) How do clinical and demographic traits correlate with growth patterns (e.g., multiplicity, size)? The primary objective is to identify epidemiological risk factors using integrated clinical and omics data, while secondary aims include comparing risk factors across subtypes and characterizing high-risk populations to guide early detection.
By integrating UKB’s population-level genetic with detailed clinical records, this study will advance understanding of lipoma etiology, offering evidence for targeted prevention and personalized management.
